Ki-Hye Kim

Ki-Hye Kim

Auto-generated profile, based on publicly available information

Ki-Hye Kim

Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
JSJEEVA SUBBIAH
JEEVA SUBBIAH
KKKi-Hye Kim
Ki-Hye Kim
CSChong Shin
Chong Shin
BWBao-Zhong Wang
Bao-Zhong Wang
SKSang-Moo Kang
Sang-Moo Kang
With the success of COVID-19 vaccines, newly created mRNA vaccines against other infectious diseases are beginning to emerge. Here, we review the structural elements required for designing mRNA vaccine constructs for effective in vitro synthetic transcription reactions. The unprecedently speedy development of mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was enabled with previous innovations in nucleoside modifications during in vitro transcription and lipid nanoparticle delivery materials of mRNA. Recent updates are briefly described in the status of mRNA vaccines against SARS-CoV-2, influenza virus, and other viral pathogens. Unique features of mRNA vaccine platforms and future perspectives are discussed.

18 December 2021 in Antiviral Research
Verified
Journal Article
Closed access
Noopur BhatnagarNoopur Bhatnagar
Noopur Bhatnagar
KKKi-Hye Kim
Ki-Hye Kim
JSJeeva Subbiah
Jeeva Subbiah
BPBo Ryoung Park
Bo Ryoung Park
EKEun-Ju Ko
Eun-Ju Ko
SKSang-Moo Kang
Sang-Moo Kang

18 April 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MKMin-Chul Kim
Min-Chul Kim
KKKi-Hye Kim
Ki-Hye Kim
JLJeong Woo Lee
Jeong Woo Lee
YLYu-Na Lee
Yu-Na Lee
Hyo-Jick ChoiHyo-Jick Choi
Hyo-Jick Choi
SKSang-Moo Kang
Sang-Moo Kang
It is a high priority to develop a simple and effective delivery method for a cross-protective influenza vaccine. We investigated skin immunization by microneedle (MN) patch with human influenza split vaccine and virus-like particles containing heterologous M2 extracellular (M2e) domains (M2e5x virus-like particles (VLP)) as a cross-protective influenza vaccine candidate. Co-delivery of influenza split vaccine and M2e5x VLP to the skin by MN patch was found to confer effective protection against heterosubtypic influenza virus by preventing weight loss and reducing lung viral loads. Compared to intramuscular immunization, MN-based delivery of combined split vaccine and M2e5x VLPs shaped cellular immune responses toward T helper type 1 responses increasing IgG2a isotype antibodies as well as IFN-γ producing cells in mucosal and systemic sites. This study provides evidence that potential immunological and logistic benefits of M2e5x VLP with human influenza split vaccine delivered by MN patch can be used to develop an easy-to-administer cross-protective influenza vaccine.

29 March 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
KKKi-Hye Kim
Ki-Hye Kim
Noopur BhatnagarNoopur Bhatnagar
Noopur Bhatnagar
JSJEEVA SUBBIAH
JEEVA SUBBIAH
JOJudy Oh
Judy Oh
BPBo Ryoung Park
Bo Ryoung Park
SKSang-Moo Kang
Sang-Moo Kang
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be expanding the pandemic disease across the globe. Although SARS-CoV-2 vaccines were rapidly developed and approved for emergency use of vaccination in humans, supply and production difficulties are slowing down the global vaccination program. The efficacy of many different versions of vaccine candidates and adjuvant effects remain unknown, particularly in the elderly. In this study, we compared the immunogenic properties of SARS-CoV-2 full-length spike (S) ectodomain in young adult and aged mice, S1 with receptor binding domain, and S2 with fusion domain. Full-length S was more immunogenic and effective in inducing IgG antibodies after low dose vaccination, compared to the S1 subunit. Old-aged mice induced SARS-CoV-2 spike-specific IgG antibodies with neutralizing activity after high dose S vaccination. With an increased vaccine dose, S1 was highly effective in inducing neutralizing and receptor-binding inhibiting antibodies, although both S1 and S2 subunit domain vaccines were similarly immunogenic. Adjuvant effects were significant for effective induction of IgG1 and IgG2a isotypes, neutralizing and receptor-binding inhibiting antibodies, and antibody-secreting B cell and interferon-γ secreting T cell immune responses. Results of this study provide information in designing SARS-CoV-2 spike vaccine antigens and effective vaccination in the elderly.

6 July 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
Noopur BhatnagarNoopur Bhatnagar
Noopur Bhatnagar
KKKi-Hye Kim
Ki-Hye Kim
JSJeeva Subbiah
Jeeva Subbiah
SMSakinah Muhammad-Worsham
Sakinah Muhammad-Worsham
BPBo Ryoung Park
Bo Ryoung Park
SKSang-Moo Kang
Sang-Moo Kang
With concerns about the efficacy of repeat annual influenza vaccination, it is important to better understand the impact of priming vaccine immunity and develop an effective vaccination strategy. Here, we determined the impact of heterologous prime-boost vaccination on inducing broader protective immunity compared to repeat vaccination with the same antigen. The primed mice that were intramuscularly boosted with a heterologous inactivated influenza A virus (H1N1, H3N2, H5N1, H7N9, H9N2) vaccine showed increased strain-specific hemagglutination inhibition titers against prime and boost vaccine strains. Heterologous prime-boost vaccination of mice with inactivated viruses was more effective in inducing high levels of IgG antibodies specific for groups 1 and 2 hemagglutinin stalk domains, as well as cross-protection, compared to homologous vaccination. Both humoral and T cell immunity were found to play a critical role in conferring cross-protection by heterologous prime-boost vaccination. These results support a strategy to enhance cross-protective efficacy by heterologous prime-boost influenza vaccination.

3 November 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
TKTatiana Kotomina
Tatiana Kotomina
LRLarisa G. Rudenko
Larisa G. Rudenko
KKKi-Hye Kim
Ki-Hye Kim
BPBo Ryoung Park
Bo Ryoung Park
YJYu-Jin Jung
Yu-Jin Jung
LRLarisa G. Rudenko
Larisa G. Rudenko
Influenza viruses constantly evolve, reducing the overall protective effect of routine vaccination campaigns. Many different strategies are being explored to design universal influenza vaccines capable of protecting against evolutionary diverged viruses. The ectodomain of influenza A M2e protein (M2e) is among the most promising targets for universal vaccine design. Here, we generated two recombinant live attenuated influenza vaccines (LAIVs) expressing additional four M2e tandem repeats (4M2e) from the N-terminus of the viral hemagglutinin (HA) protein, in an attempt to enhance the M2e-mediated cross-protection. The recombinant H1N1+4M2e and H3N2+4M2e viruses retained growth characteristics attributable to traditional LAIV viruses and induced robust influenza-specific antibody responses in BALB/c mice, although M2e-specific antibodies were raised only after two-dose vaccination with LAIV+4M2e viruses. Mice immunized with either LAIV or LAIV+4M2e viruses were fully protected against a panel of heterologous influenza challenge viruses suggesting that antibody and cell-mediated immunity contributed to the protection. The protective role of the M2e-specific antibody was seen in passive serum transfer experiments, where enhancement in the survival rates between classical LAIV and chimeric H3N2+4M2e LAIV was demonstrated for H3N2 and H5N1 heterologous challenge viruses. Overall, the results of our study suggest that M2e-specific antibodies induced by recombinant LAIV+4M2e in addition to cellular immunity by LAIV play an important role in conferring protection against heterologous viruses.